Answers are grounded in this paper and cite their sources.
Visceral leishmaniasis (VL), also known as kala-azar, is a potentially fatal neglected tropical disease caused primarily by Leishmania donovani and Leishmania infantum. Despite advances in antileishmanial therapy, its management remains challenging due to treatment-associated toxicity, drug resistance, high treatment costs, and limitations in drug administration. Amphotericin B (AmB), a polyene macrolide antibiotic with potent antileishmanial activity, has emerged as an important therapeutic agent in the management of VL. However, conventional amphotericin B deoxycholate is associated with dose-limiting nephrotoxicity, infusion-related adverse reactions, and the requirement for intravenous administration. To overcome these limitations, lipid-based formulations, particularly liposomal amphotericin B, have been developed to improve drug distribution, enhance tolerability, and maintain therapeutic efficacy. Formulations such as AmBisome and the indigenous Indian preparation FUNGISOME have demonstrated considerable clinical relevance, although their cost, parenteral administration, and storage requirements remain important challenges. In this context, oral drug delivery has gained attention as a potential alternative to conventional injectable therapy. Self-emulsifying drug delivery systems (SEDDS) and self-nanoemulsifying drug delivery systems (SNEDDS) offer promising approaches for improving the dispersion and delivery of poorly water-soluble drugs such as amphotericin B. Preclinical investigations of oral lipid-based formulations, including iCo-010, have demonstrated encouraging antileishmanial activity and reductions in parasite burden in experimental models. Nevertheless, poor gastrointestinal absorption, complex physicochemical properties, formulation stability, and potential toxicity remain significant barriers to successful oral delivery. This review discusses the therapeutic role of conventional and liposomal amphotericin B in VL, the formulation strategies developed to improve its safety and efficacy, and the emerging potential of SEDDS-based oral delivery. It also highlights future research requirements concerning formulation optimization, pharmacovigilance, preclinical and clinical evaluation, and regulatory considerations for translating oral amphotericin B formulations into clinically viable and accessible therapeutic alternatives.
No takes yet. Share an insight, caveat, or question.
Salunkhe et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: